NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/03/2026
Back to search
Official data from USPTO
NEXRETYS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
58
Latest update
03/03/2026
Trademark type
Word
Nice classes
5
Filing date
11/06/2020
Registration date
03/03/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/03/2026
Last transaction
03/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
03
Owner location
Shanghai, CN
Examiner
POWERS, ALEXANDER L
Law office
L10
Current location
INTENT TO USE SECTION
Holders and representatives
Holders
EVIVE BIOTECHNOLOGY (SHANGHAI) LTD.
EVIVE BIOTECHNOLOGY (SHANGHAI) LTD.
Generon (Shanghai) Corporation Ltd.
Representatives
Muzamil Huq MORRISON & FOERSTER LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Chemical pharmaceutical preparations in the nature of chemical preparations for pharmaceutical purposes for the treatment or prevention of inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; human medicines for the treatment or prevention of inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; biochemical drugs for the treatment or prevention of inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; pharmaceutical preparations for the treatment or prevention of inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; medicinal capsules for the treatment or prevention of inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; medical chemical preparations in the nature of chemical preparations for medical purposes for the treatment or prevention of inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; medical biological preparations for the treatment or prevention of inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; medical ointmentsmedicated ointments for treating or preventing inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; medical drugs for the treatment or prevention of inflammatory diseasegraft-versus-host diseaseliver diseaseslung diseasespancreatic diseasesintestinal disordersnerve damage diseasesneurodegenerative diseasessystemic inflammatory response syndromesepsismultiple organ dysfunction syndromemetabolic disorders; medical diagnostic preparations
Publications
History of USPTO decisions and trademark events.
58 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
03/03/2026
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
02/09/2026
IUCN
NOTICE OF ALLOWANCE CANCELLED
02/06/2026
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
02/06/2026
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/23/2025
EX5G
SOU EXTENSION 5 GRANTED
12/22/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
12/22/2025
EXT5
SOU EXTENSION 5 FILED
08/04/2025
EEXT
SOU TEAS EXTENSION RECEIVED
08/04/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/01/2025
EX4G
SOU EXTENSION 4 GRANTED
02/01/2025
EXT4
SOU EXTENSION 4 FILED
01/31/2025
EEXT
SOU TEAS EXTENSION RECEIVED
01/31/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/24/2024
EX3G
SOU EXTENSION 3 GRANTED
07/23/2024
EXT3
SOU EXTENSION 3 FILED
07/23/2024
EEXT
SOU TEAS EXTENSION RECEIVED
07/22/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/07/2024
EX2G
SOU EXTENSION 2 GRANTED
02/05/2024
EXT2
SOU EXTENSION 2 FILED
02/05/2024
EEXT
SOU TEAS EXTENSION RECEIVED
02/05/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/22/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/22/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/22/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/03/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/03/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/03/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/09/2023
EX1G
SOU EXTENSION 1 GRANTED
08/07/2023
EXT1
SOU EXTENSION 1 FILED
08/07/2023
EEXT
SOU TEAS EXTENSION RECEIVED
08/07/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/07/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/13/2022
PUBO
PUBLISHED FOR OPPOSITION
12/13/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/23/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/10/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/10/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/10/2022
ALIE
ASSIGNED TO LIE
11/08/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
09/26/2022
DOCK
ASSIGNED TO EXAMINER
05/31/2022
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
04/20/2022
GNSI
INQUIRY TO SUSPENSION E-MAILED
04/20/2022
CNSI
SUSPENSION INQUIRY WRITTEN
04/20/2022
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
10/04/2021
GNSL
LETTER OF SUSPENSION E-MAILED
10/04/2021
CNSL
SUSPENSION LETTER WRITTEN
10/04/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/01/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/30/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/30/2021
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
06/16/2021
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
04/16/2021
GPRA
PRIORITY ACTION E-MAILED
04/16/2021
CPRA
PRIORITY ACTION WRITTEN
04/16/2021
DOCK
ASSIGNED TO EXAMINER
04/14/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/06/2021
NWAP
NEW APPLICATION ENTERED
11/10/2020
Continuous trademark protection
Get notified about every new filing that threatens NEXRETYS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.